Literature DB >> 2548134

Mixed müllerian tumors of the uterus: a clinicopathologic study.

T V Dinh1, R E Slavin, B S Bhagavan, E V Hannigan, E M Tiamson, R B Yandell.   

Abstract

Forty-seven cases of mixed müllerian tumors of the uterus were analyzed clinically and pathologically. All patients but one were postmenopausal. Vaginal bleeding was the most frequent presenting symptom, followed by abdominal mass and pelvic pain. Long-term survival was found only in those cases in which the tumor was localized to the uterus (surgical stage I), particularly if it arose from a benign endometrial polyp. No correlation could be established between survival and tumor size, depth of myometrial invasion, or histologic type of sarcoma. Tumors arising after previous irradiation had a poor prognosis. Treatment included surgery, radiation, and chemotherapy. The cumulative probability of 5-year survival was 35%.

Entities:  

Mesh:

Year:  1989        PMID: 2548134

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  3 in total

1.  Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers.

Authors:  Ashley Sinclair Felix; Roslyn A Stone; Robert Bowser; Mamatha Chivukula; Robert P Edwards; Joel L Weissfeld; Faina Linkov
Journal:  Int J Gynecol Cancer       Date:  2011-07       Impact factor: 3.437

2.  Sarcomatous lesions in CBA female mice treated with 1,2-dimethylhydrazine: independent primaries or metastases?

Authors:  L S Trukhanova; V S Turusov
Journal:  Clin Exp Metastasis       Date:  1995-09       Impact factor: 5.150

3.  Clinical significance of radiotherapy in patients with primary uterine carcinosarcoma: a multicenter retrospective study (KROG 13-08).

Authors:  Jihye Cha; Young Seok Kim; Won Park; Hak Jae Kim; Joo Young Kim; Jin Hee Kim; Juree Kim; Won Sup Yoon; Jun Won Kim; Yong Bae Kim
Journal:  J Gynecol Oncol       Date:  2016-07-11       Impact factor: 4.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.